PTGX - NASDAQ

Protagonist Therapeutics, Inc.

PTGX·NASDAQ

$95.41

+1.5%

HealthcareBiotechnology

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$6.14B

EPS-2.0500

P/E Ratio-46.54

Earnings Date07/30/2026

669.89M

Assets

-10%

3Y+170.0%

5Y+106.0%

10Y+613.0%

55.19M

Total Liabilities

-21%

3Y+71.0%

5Y+23.0%

10Y+758.0%

614.71M

Total Equity

-9%

3Y+185.0%

5Y+120.0%

10Y-1052.0%

Protagonist Therapeutics, Inc. Funding & Solvency Profile

PTGX · NASDAQ

Current Assets

Cash & Cash Equivalents128.39M

Net Receivables4.50M

Inventory0.00

Other Current Assets0.00

Total Current Assets578 M

Non-Current Assets

Property, Plant & Equipment11.69M

Goodwill & Intangible Assets0.00

Long-Term Investments78.92M

Other Non-Current Assets0.00

Total Non-Current Assets91 M

Total Assets

669.89M

Financial Health Analysis

Current Ratio

12.71x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.09x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

532 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

86% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Protagonist Therapeutics, Inc. Balance Sheet

PTGX • NASDAQ

Protagonist Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	128.4M	97.2M	186.7M	125.7M	123.7M	117.4M	33M	82.2M	106M	21.1M	4.1M	9.3M
Short-Term Investments	439M	321.7M	154.9M	111.6M	203.2M	188.5M	100M	46.6M	38M	56.5M	7.9M	0.0
Cash & Short-Term Investments	567.4M	418.9M	341.6M	237.4M	326.9M	305.8M	133M	128.9M	144M	77.6M	11.9M	9.3M
Net Receivables	4.5M	168.5M	10.3M	52K	5.3M	3.8M	6.8M	4.6M	1.8M	2.2M	715K	523K
Accounts Receivables	121K	165M	10M	10K	1.6M	2.4M	6.8M	4.6M	1.8M	0.0	0.0	0.0
Other Receivables	4.4M	3.5M	332K	42K	3.8M	1.4M	0.0	0.0	0.0	2.2M	715K	523K
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1M	-8.7M	-7.7M	0.0	10K
Prepaids	5.7M	4.2M	3.6M	5.7M	8.5M	6M	4.8M	2.1M	3.6M	2.9M	1.3M	0.0
Other Current Assets	0.0	0.0	0.0	0.0	0.0	10K	754K	-205K	10.2M	8.2M	315K	56K
Total Current Assets	577.6M	591.6M	355.6M	243.1M	340.7M	315.6M	145.3M	137.5M	150.9M	83.2M	14.2M	9.9M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	11.7M	12.6M	2.1M	4.6M	6.7M	6.4M	7.7M	861K	879K	562K	609K	415K
Goodwill & Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-450K	0.0	0.0	0.0	0.0
Long-Term Investments	78.9M	140.3M	0.0	0.0	0.0	2M	0.0	450K	11.5M	10.2M	30K	0.0
Tax Assets	1.7M	0.0	0.0	0.0	0.0	0.0	1.4M	658K	0.0	0.0	0.0	0.0
Other Non-Current Assets	0.0	225K	225K	225K	225K	450K	450K	450K	450K	34K	0.0	0.0
Total Non-Current Assets	92.3M	153.1M	2.4M	4.9M	7M	8.9M	9.6M	2M	12.8M	10.7M	639K	415K
Total Assets	669.9M	744.7M	358M	247.9M	347.7M	324.5M	154.9M	139.5M	163.7M	94M	14.8M	10.3M
LIABILITIES
CURRENT LIABILITIES
Total Payables	5.3M	4.3M	871K	4.1M	2M	3.2M	2.9M	5.7M	1.3M	1.2M	1.2M	349K
Accounts Payable	5.3M	1.6M	772K	3.6M	1.6M	3.1M	2.8M	5.7M	1.3M	1.2M	1.2M	349K
Other Payables	0.0	2.7M	99K	415K	407K	82K	122K	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	12.8M	0.0	12.5M	19.6M	30.2M	12M	7.6M	2.7M	2.7M	5.2M	1.7M	1M
Short Term Debt	2.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	510K	1.1M	2.5M	2.2M	1.5M	1.3M	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	2.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	9.6M	18.9M	0.0	69K	2.5M	17.2M	19M	8.2M	31.8M	0.0	0.0	0.0
Other Current Liabilities	15.5M	23.7M	6.8M	5M	7.1M	6.4M	4.6M	9.5M	6.8M	120K	149K	0.0
Total Current Liabilities	45.4M	47.4M	21.3M	31.2M	44M	40.2M	35.4M	26.2M	42.6M	6.4M	3.1M	1.4M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	9.8M	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	23.8M	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	1.7M	0.0	221K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	11.7M	-221K	0.0	0.0	121K	0.0	799K	547K	0.0	2.1M	1M
Total Non-Current Liabilities	9.7M	22M	0.0	1.1M	3.7M	4.6M	39.5M	799K	547K	0.0	2.1M	1M
Capital Lease Obligations	8M	10.9M	1.1M	3.7M	5.9M	6M	7.2M	0.0	0.0	0.0	0.0	0.0
Total Liabilities	55.2M	69.4M	21.3M	32.3M	47.7M	44.9M	75M	27M	43.1M	6.4M	5.2M	2.4M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	94M	37M	20.6M
Common Stock	1K	1K	1K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Additional Paid-In Capital	1.1B	1B	952.5M	752.7M	709.7M	563.4M	297.8M	253.2M	222.2M	152.4M	118K	37K
Retained Earnings	-470.7M	-340.5M	-615.7M	-536.8M	-409.4M	-283.8M	-217.7M	-140.5M	-101.6M	-64.6M	-27.4M	-12.6M
Accumulated Other Comprehensive Income/Loss	641K	-82K	-105K	-359K	-299K	28K	-221K	-233K	-6K	-245K	-102K	-100K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-94M	0.0	0.0
Total Stockholders' Equity	614.7M	675.3M	336.7M	215.6M	300M	279.6M	80M	-140.5M	-101.6M	-64.6M	9.6M	8M
Total Equity	614.7M	675.3M	336.7M	215.6M	300M	279.6M	80M	-140.5M	-101.6M	-64.6M	9.6M	8M
SUMMARY
Total Liabilities & Equity	669.9M	744.7M	358M	247.9M	347.7M	324.5M	154.9M	-113.5M	-58.4M	-58.2M	14.8M	10.3M
Total Investments	517.9M	461.9M	154.9M	111.6M	203.2M	190.5M	100M	46.6M	49.4M	66.7M	7.9M	0.0
Total Debt	10.3M	10.9M	1.1M	3.7M	5.9M	6M	17M	0.0	0.0	0.0	0.0	0.0
Net Debt	-118.1M	-86.4M	-185.6M	-122.1M	-117.8M	-111.4M	-16M	-82.2M	-106M	-21.1M	-4.1M	-9.3M
Shares Outstanding	62,512,694	62,512,694	62,512,694	62,512,694	62,512,694	62,512,694	62,512,694	62,512,694	62,512,694	62,512,694	62,512,694	62,512,694

SEC Filings

PTGX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 05, 2026	May 05, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 05, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	June 17, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 25, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 25, 2026	February 25, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 06, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 06, 2025	November 06, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 06, 2025	June 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 06, 2025	August 06, 2025	2025	View Filing

Showing 1 to 10 of 163 filings

Related Guides

Blog Categories

Continue your PTGX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.